Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic trioxide-based sequential chemotherapy for relapsed or refractory ovarian cancer
ChiCTR2400093196Phase 4Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Nov 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of arsenic trioxide, paclitaxel, fluorouracil, bevacizumab and pegylated liposomal doxorubicin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 arms), sponsored by Peking University People's Hospital. Primary endpoint: progression-free survival. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
arsenic trioxidepaclitaxelfluorouracilbevacizumabpegylated liposomal doxorubicin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2400093196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093196.